Get the Stockscreener App
697.08
0.34%
2.38
After Hours:
697.08
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Mckesson Corporation stock is traded at $697.08, with a volume of 1.01M.
It is up +0.34% in the last 24 hours and up +6.38% over the past month.
McKesson Corp is one of three leading pharmaceutical wholesalers in the us engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with Cencora and Cardinal Health, the three account for over 90% of the us pharmaceutical wholesale industry. Outside the us market, McKesson engages in pharmaceutical wholesale and distribution in Canada. Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
See More
Previous Close:
$694.70
Open:
$688.72
24h Volume:
1.01M
Relative Volume:
1.12
Market Cap:
$86.97B
Revenue:
$344.58B
Net Income/Loss:
$2.83B
P/E Ratio:
31.92
EPS:
21.84
Net Cash Flow:
$1.63B
1W Performance:
+2.61%
1M Performance:
+6.38%
6M Performance:
+37.03%
1Y Performance:
+32.54%
1-Day Range:
$686.64
$702.00
1-Week Range:
$673.46
$702.21
52-Week Range:
$464.42
$728.32
Mckesson Corporation Stock (MCK) Company Profile
Name
Mckesson Corporation
Sector
Industry
Phone
972-446-4800
Address
6555 STATE HIGHWAY 161, IRVING, TX
Compare MCK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MCK
Mckesson Corporation
|
697.08 | 86.97B | 344.58B | 2.83B | 1.63B | 21.84 |
|
COR
Cencora Inc
|
286.74 | 55.07B | 303.19B | 1.40B | -638.10M | 7.03 |
|
CAH
Cardinal Health Inc
|
134.71 | 32.56B | 222.16B | 1.31B | -486.00M | 5.36 |
|
HSIC
Henry Schein Inc
|
64.73 | 8.04B | 12.50B | 314.00M | 421.00M | 2.44 |
|
OMI
Owens Minor Inc
|
6.93 | 534.60M | 10.42B | -38.77M | 323.54M | -0.51 |
Mckesson Corporation Stock (MCK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-04-24 | Resumed | Mizuho | Neutral |
| Nov-07-24 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-05-24 | Reiterated | Leerink Partners | Outperform |
| Aug-08-24 | Reiterated | Mizuho | Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Overweight |
| Jul-06-22 | Downgrade | Argus | Buy → Hold |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Feb-04-22 | Downgrade | Deutsche Bank | Buy → Hold |
| Jan-07-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Nov-02-21 | Reiterated | Barclays | Overweight |
| Nov-02-21 | Reiterated | BofA Securities | Buy |
| Nov-02-21 | Reiterated | Evercore ISI | Outperform |
| Nov-02-21 | Reiterated | Jefferies | Buy |
| Mar-30-21 | Upgrade | Argus | Hold → Buy |
| Nov-02-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-04-20 | Upgrade | Deutsche Bank | Hold → Buy |
| May-22-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| May-15-20 | Upgrade | UBS | Neutral → Buy |
| Apr-23-20 | Resumed | Credit Suisse | Neutral |
| Mar-18-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-13-20 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-10-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Aug-05-19 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jul-22-19 | Initiated | Guggenheim | Neutral |
| Jan-17-19 | Initiated | UBS | Neutral |
| Oct-26-18 | Reiterated | Barclays | Equal Weight |
| Jul-20-18 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-29-18 | Reiterated | Leerink Partners | Mkt Perform |
| Mar-08-18 | Initiated | Barclays | Equal Weight |
| Feb-27-18 | Resumed | BofA/Merrill | Buy |
| Feb-02-18 | Reiterated | Mizuho | Neutral |
| Jan-24-18 | Upgrade | Jefferies | Hold → Buy |
View All
Mckesson Corporation Stock (MCK) Latest News
Jim Cramer Labels McKesson Corporation (MCK) a “Money Machine – A Must-Own Middleman” - Insider Monkey
McKesson Launches Precision Care Companion for Biomarker-Driven Cancer Care - HIT Consultant
McKesson is medicine for Elite Investors in market chaos - Citywire
Jim Cramer’s List of 16 Stocks to Buy Right Now - Insider Monkey
Citigroup Adjusts Price Target on McKesson to $800 From $685, Maintains Buy Rating - marketscreener.com
McKesson provides Elite Investors with medicine for market choas - Citywire
McKesson (MCK) Ascends While Market Falls: Some Facts to Note - Yahoo Finance
McKesson Launches Collaboration to Boost Precision Oncology Adoption - Inside Precision Medicine
McKesson (NYSE:MCK) Launches Precision Care Initiative Transforming Oncology Treatment - Yahoo Finance
Jim Cramer: McKesson (MCK) Is a “Money Machine” – Funds Keep Flowing In - Yahoo Finance
McKesson Unveils Precision Care Companion, Revolutionizing Precision Medicine in Community Oncology - Business Wire
McKesson Corporation (MCK): Among the Best Value Dividend Stocks to Buy According to Billionaires - Yahoo Finance
McKesson Careers | The future of health starts with you. - McKesson Careers
3 Dividend Stocks Built for Stability as Growth Trades Cool Off - Investing.com
Middlemen Always Work.” – Jim Cramer’s Love for McKesson Corporation (MCK) - Insider Monkey
GS1 US to host webinar on McKesson, Target supply chain traceability - Supermarket Perimeter
GS1 to host webinar on McKesson, Target supply chain traceability - Supermarket Perimeter
McKesson (MCK) Sees Price Target Boost to $755 by BofA | CAH Sto - GuruFocus
McKesson To Rally More Than 11%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
McKesson and Wegmans: A Long-Standing Partnership in Advancing Pharmacy - NEWS CHANNEL NEBRASKA
Why the Market Dipped But McKesson (MCK) Gained Today - Yahoo Finance
Investors Heavily Search McKesson Corporation (MCK): Here is What You Need to Know - Yahoo Finance
Jonathan Jackson from Illinois’s 1st district makes notable trades in Microsoft, Salesforce, and McKesson - Investing.com India
This Medical Supplies Distributor Dodges A Tariff Bullet - Investor's Business Daily
Evercore ISI Adjusts Price Target on McKesson to $740 From $675, Maintains Outperform Rating - MarketScreener
McKesson (MCK) Stock Moves -1.38%: What You Should Know - Yahoo Finance
McKesson opens registration for 2025 ideaShare conference - Drug Store News
Registration Opens for Annual McKesson ideaShare Conference - Yahoo Finance
Quad-C Management Completes the Sale of PRISM Vision to McKesson - PR Newswire
Quad-C sells stake in Prism Vision to McKesson Corporation - pehub.com
McKesson Corporation (MCK): Jim Cramer’s Top Pick – Why He Thinks McKesson Can ‘Jack Prices Up’ - Insider Monkey
Zacks Research Brokers Lift Earnings Estimates for McKesson - Defense World
Rite Aid weighs repeat bankruptcy filing, WSJ reports - MarketScreener
McKesson In Huge Group New To IBD 50: Check Out Which Stocks Just Came On – And Off – IBD's Top Stock Screens - Investor's Business Daily
McKesson stock soars to all-time high of $726.13 By Investing.com - Investing.com South Africa
McKesson stock soars to all-time high of $726.13 - Investing.com
Mizuho raises McKesson stock target to $690, maintains neutral By Investing.com - Investing.com South Africa
MCK Stock Gains as PRISM Acquisition Adds High-Growth Business - TradingView
McKesson Corporation completed the acquisition of 80% stake in PRISM Vision Group from Quad-C Management, Inc. - MarketScreener
Deutsche Bank Adjusts Price Target on McKesson to $692 From $700, Maintains Buy Rating - MarketScreener
Mizuho Adjusts Price Target on McKesson to $690 From $630, Maintains Neutral Rating - MarketScreener
McKesson price target raised to $690 from $630 at Mizuho - TipRanks
Mizuho raises McKesson stock target to $690, maintains neutral - Investing.com India
McKesson Shares Up Over 2% After Key Signal - Benzinga
McKesson Gets Drugs to Patients. Buy the Stock for Healthy Returns. - Barron's
McKesson (MCK) Poised for Growth in Pharmaceutical Distribution - GuruFocus
Whistleblower Asks Justices to Revive Suit Against McKesson Unit - Bloomberg Law News
McKesson: Morgan Stanley's Top Choice For Pharmaceutical Gains - Finimize
McKesson Likely to See Strong Growth Amid Favorable Pharma Sector, Morgan Stanley Says - MarketScreener
McKesson completes $850M majority stake purchase in eye care company - The Business Journals
Leerink Partners Adjusts PT on McKesson to $745 From $732, Maintains Outperform Rating - MarketScreener
Mckesson Corporation Stock (MCK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):